

CLAIMS

1. A compound represented by Formula (**VIId-1**) or (**VIIe-1**), or a pharmaceutically acceptable salt thereof:




(VIId-1)




(VIIe-1)

wherein m3 is 0, 1, 2, or 3; R_{21} at each occurrence is halogen; R_{22} is halogen; R_{23} is hydrogen or halogen; n at each occurrence is independently selected from 0, 1, 2, or 3; E at each occurrence is independently selected from $-C(R_{10})_2-$, -O- and $-N(R_{10})-$; R_{10} at each occurrence is independently selected from the group consisting of hydrogen, halogen, -CN, $-NO_2$, optionally substituted $-C_1$-C_6 alkyl, optionally substituted $–C_2$-C_8 alkenyl, optionally substituted $–C_2$-C_8 alkynyl, optionally substituted $–C_3$-C_8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, and $–L_1$-R_1; wherein L_1 is –O-, -S-, $-NR_1-$, -C(O)-, -C(O)O-, -OC(O)-, $-C(O)N(R_1)-$, $-N(R_1)C(O)-$, $-OC(O)N(R_1)-$, $-N(R_1)C(O)O-$, $-N(R_1)C(O)N(R_1)-$, -S(O)-, $-S(O)_2-$, $-S(O)_2N(R_1)-$, $-N(R_1)S(O)_2-$; R_1 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted $-C_1$-C_6 alkyl; alternatively, two adjacent R_{10} groups are taken together with the carbon or nitrogen atoms to which they are attached to form an olefinic or iminic double-bond or a fused ring; or two geminal R_{10} groups together form an oxo, an optionally substituted olefin, an optionally substituted oxime, or an additional spiro ring.

2. The compound of claim 1, represented by Formula Formula (VIIc-2) or (VIId-2),



(VIIc-2)



(VIId-2)

or a pharmaceutically acceptable salt thereof, wherein

n at each occurrence is independently selected from 0 and 1;

m_4 is 0, 1 or 2; and

R_{30} is hydrogen or optionally substituted $-C_1$-C_6 alkyl.

3. The compound of claim 2 which is represented by Formula (VIId-2), or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 or claim 3, wherein

R_{10} is halogen, hydroxyl, or optionally substituted C_1-C_3 alkyl; and

R_{30} is hydrogen.

5. The compound of any one of claims 2 to 4 wherein

R_{21} at each occurrence is fluorine;

R_{22} is fluorine or chlorine;





R_{23} is hydrogen or fluorine;












R_{10} is halogen, hydroxyl, hydroxymethyl, fluoromethyl, trifluoromethyl or methoxymethyl; and











R_{30} is hydrogen.











6. The compound of any one of claims 2 to 5 wherein R_{23} is fluorine.










7. The compound of claim 1 selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:











Compound	Structure
1	
44	
49	
60	










106	
119	
120	
126	
127	
128	
129	
130	
131	
132	
133	










135	
136	
137	
139	
140	
141	
142	
146	
149	
150	











151	
152	
153	
154	
155	
156	
157	
158	
160	
161	










162	
163	
164	
167	
168	
169	
170	
171	
172	










173	
183	
185	
186	
187	
188	
192	
197	
200	
206	










207	
208	
209	
210	
211	
212	
213	
214	
215	











216	
217	
218	
219	
220	
221	
222	
223	
225	











226	
239	
240	
241	
242	
243	
244	
245	
246	
247	










248	
249	
250	
251	
252	
253	
254	
255	
256	










257	
258	
259	
260	
261	
262	
263	
264	
265	










266	
267	
268	
269	
270	
271	
272	
273	
274	










275	
276	
277	
278	
279	
280	
281	
282	
283	
284	










285	
286	
288	
289	
290	
291	
292	
293	
294	
295	










296	
297	
298	
300	
301	
302	
303	
304	
305	










306	
307	
308	
309	
310	
311	
312	
313	
314	










315	
316	
317	
318	
319	
320	
321	
322	
323	











324	
325	
326	
327	
328	
329	
330	
331	
332	










334	
335	
336	
337	
338	
339	
340	
341	
342	










343	
344	
345	
346	
347	
348	
349	
350	
351	







352	
353	
354	
355	
356	
357	
358	
359	
360	

361	
362	
363	
364	
365	
366	
367	
368	
369	

370	
371	
372	
373	
374	
375	
376	
377	
378	
379	

380	
381	
382	
383	
384	
385	
386	
387	
388	

389	
390	
391	
392	
393	
394	
395	
396	
397	

398	
407	
408	
409	
413	
415	

.

8. A pharmaceutical composition, comprising a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier or excipient.

9. Use of the compound according to any one of claims 1 to 7 in the manufacture of a medicament for treating or preventing an HBV infection.